Meeting of the National Vaccine Advisory Committee, 27061-27062 [2012-10986]

Download as PDF Federal Register / Vol. 77, No. 89 / Tuesday, May 8, 2012 / Notices Federal Communications Commission. Troy F. Tanner, Deputy Chief, International Bureau. [FR Doc. 2012–11071 Filed 5–7–12; 8:45 am] BILLING CODE 6712–01–P FEDERAL RESERVE SYSTEM Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)). The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than May 23, 2012. A. Federal Reserve Bank of New York (Ivan Hurwitz, Vice President) 33 Liberty Street New York, New York 10045–0001: 1. Preston D. Pinkett, III, Gladstone, New Jersey; to acquire voting shares of City National Bancshares Corporation, and thereby indirectly acquire voting shares of City National Bank of New Jersey, both in Newark, New Jersey. Board of Governors of the Federal Reserve System, May 3, 2012. Margaret McCloskey Shanks, Associate Secretary of the Board. [FR Doc. 2012–11039 Filed 5–7–12; 8:45 am] BILLING CODE 6210–01–P FEDERAL RESERVE SYSTEM srobinson on DSK4SPTVN1PROD with NOTICES Formations of, Acquisitions by, and Mergers of Bank Holding Companies The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies VerDate Mar<15>2010 17:33 May 07, 2012 Jkt 226001 owned by the bank holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than June 1, 2012. A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690–1414: 1. Johnston Growth Corporation, Johnston, Iowa; to become a bank holding company following the conversion of its subsidiary, Charter Bank, Johnston, Iowa, from a federally chartered savings association to a state chartered bank. Board of Governors of the Federal Reserve System, May 3, 2012. Margaret McCloskey Shanks, Associate Secretary of the Board. [FR Doc. 2012–11041 Filed 5–7–12; 8:45 am] 27061 The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 23, 2012. A. Federal Reserve Bank of Cleveland (Nadine Wallman, Vice President) 1455 East Sixth Street Cleveland, Ohio 44101–2566: 1. Fifth Third Bancorp, Cincinnati, Ohio; to acquire additional voting shares of Fifth Third Community Development Corp., Valparaiso, Indiana, and thereby engage in community development activities, pursuant to section 225.28(b)(12) of Regulation Y. Board of Governors of the Federal Reserve System, May 3, 2012. Margaret McCloskey Shanks, Associate Secretary of the Board. [FR Doc. 2012–11040 Filed 5–7–12; 8:45 am] BILLING CODE 6210–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the National Vaccine Advisory Committee Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health. ACTION: Notice of meeting. AGENCY: BILLING CODE 6210–01–P As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that the National Vaccine Advisory Committee (NVAC) will hold a meeting. The meeting is open to the public. Preregistration is required for both public attendance and comment. Individuals who wish to attend the meeting and/or participate in the public comment session should register at https:// www.hhs.gov/nvpo/nvac, email nvpo@hhs.gov, or call 202–690–5566 and provide name, organization, and email address. DATES: The meeting will be held on June 5–6, 2012. The meeting times and agenda will be posted on the NVAC Web site at https://www.hhs.gov/nvpo/ nvac as soon they become available. ADDRESSES: U.S. Department of Health and Human Services, Hubert H. Humphrey Building, Room 800, 200 Independence Avenue SW., Washington, DC 20201. SUMMARY: FEDERAL RESERVE SYSTEM Notice of Proposals To Engage in or To Acquire Companies Engaged in Permissible Nonbanking Activities The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage de novo, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States. Each notice is available for inspection at the Federal Reserve Bank indicated. PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 E:\FR\FM\08MYN1.SGM 08MYN1 27062 Federal Register / Vol. 77, No. 89 / Tuesday, May 8, 2012 / Notices FOR FURTHER INFORMATION CONTACT: National Vaccine Program Office, U.S. Department of Health and Human Services, Room 715–H, Hubert H. Humphrey Building, 200 Independence Avenue SW., Washington, DC 20201. Phone: (202) 690–5566; Fax: (202) 690– 4631; email: nvpo@hhs.gov. Pursuant to Section 2101 of the Public Health Service Act (42 U.S.C. 300aa–1), the Secretary of Health and Human Services was mandated to establish the National Vaccine Program to achieve optimal prevention of human infectious diseases through immunization and to achieve optimal prevention against adverse reactions to vaccines. The National Vaccine Advisory Committee was established to provide advice and make recommendations to the Director of the National Vaccine Program on matters related to the Program’s responsibilities. The Assistant Secretary for Health serves as Director of the National Vaccine Program. The topics to be discussed at the NVAC meeting will include seasonal influenza, implementation of the National Vaccine Plan, and vaccine research and development. The meeting agenda will be posted on the NVAC Web site: https://www.hhs.gov/nvpo/ nvac prior to the meeting. Public attendance at the meeting is limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the National Vaccine Program Office at the address/phone listed above at least one week prior to the meeting. Members of the public will have the opportunity to provide comments at the NVAC meeting during the public comment periods on the agenda. Individuals who would like to submit written statements should email or fax their comments to the National Vaccine Program Office at least five business days prior to the meeting. SUPPLEMENTARY INFORMATION: srobinson on DSK4SPTVN1PROD with NOTICES Dated: May 1, 2012. Bruce Gellin, Director, National Vaccine Program Office, Executive Secretary, National Vaccine Advisory Committee. [FR Doc. 2012–10986 Filed 5–7–12; 8:45 am] BILLING CODE 4150–44–P VerDate Mar<15>2010 17:33 May 07, 2012 Jkt 226001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–12–12IL] Agency Forms Undergoing Paperwork Reduction Act Review The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC 20503 or by fax to (202) 395–5806. Written comments should be received within 30 days of this notice. Proposed Project NIOSH Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery—NEW— Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH), Health Hazard Evaluation Program. As part of a Federal Government-wide effort to streamline the process to seek feedback from the public on service delivery, the CDC has submitted a Generic Information Collection Request (Generic ICR): ‘‘Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery ’’ to OMB for approval under the Paperwork Reduction Act (PRA) (44 U.S.C. 3501 et seq.). To request additional information, please contact Kimberly S. Lane, Reports Clearance Officer, Centers for Disease Control and Prevention, 1600 Clifton Road, MS–D74, Atlanta, GA 30333 or send an email to omb@cdc.gov. SUPPLEMENTARY INFORMATION: Title: NIOSH Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery Abstract: The information collection activity will garner qualitative customer and stakeholder feedback in an efficient, timely manner, in accordance with the Administration’s commitment to improving service delivery. By qualitative feedback we mean information that provides useful PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 insights on perceptions and opinions, but are not statistical surveys that yield quantitative results that can be generalized to the population of study. This feedback will provide insights into customer or stakeholder perceptions, experiences and expectations, provide an early warning of issues with service, or focus attention on areas where communication, training or changes in operations might improve delivery of products or services. These collections will allow for ongoing, collaborative and actionable communications between the Agency and its customers and stakeholders. It will also allow feedback to contribute directly to the improvement of program management. Feedback collected under this generic clearance will provide useful information, but it will not yield data that can be generalized to the overall population. This type of generic clearance for qualitative information will not be used for quantitative information collections that are designed to yield reliably actionable results, such as monitoring trends over time or documenting program performance. Such data uses require more rigorous designs that address: The target population to which generalizations will be made, the sampling frame, the sample design (including stratification and clustering), the precision requirements or power calculations that justify the proposed sample size, the expected response rate, methods for assessing potential nonresponse bias, the protocols for data collection, and any testing procedures that were or will be undertaken prior to fielding the study. Depending on the degree of influence the results are likely to have, such collections may still be eligible for submission for other generic mechanisms that are designed to yield quantitative results. The Agency received no comments in response to the 60-day notice published in the Federal Register on December 22, 2010 (75 FR 80542). This is a new collection of information. Respondents will be screened and selected from individuals and households, businesses, organizations, and/or State, Local or Tribal Government. Below we provide CDC’s projected annualized estimate for the next three years. There is no cost to respondents other than their time. The estimated annualized burden hours for this data collection activity are 800. E:\FR\FM\08MYN1.SGM 08MYN1

Agencies

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 77, Number 89 (Tuesday, May 8, 2012)]
[Notices]
[Pages 27061-27062]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-10986]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the National Vaccine Advisory Committee

AGENCY: Department of Health and Human Services, Office of the 
Secretary, Office of the Assistant Secretary for Health.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: As stipulated by the Federal Advisory Committee Act, the 
Department of Health and Human Services (HHS) is hereby giving notice 
that the National Vaccine Advisory Committee (NVAC) will hold a 
meeting. The meeting is open to the public. Pre-registration is 
required for both public attendance and comment. Individuals who wish 
to attend the meeting and/or participate in the public comment session 
should register at https://www.hhs.gov/nvpo/nvac, email nvpo@hhs.gov, or 
call 202-690-5566 and provide name, organization, and email address.

DATES: The meeting will be held on June 5-6, 2012. The meeting times 
and agenda will be posted on the NVAC Web site at https://www.hhs.gov/nvpo/nvac as soon they become available.

ADDRESSES: U.S. Department of Health and Human Services, Hubert H. 
Humphrey Building, Room 800, 200 Independence Avenue SW., Washington, 
DC 20201.

[[Page 27062]]


FOR FURTHER INFORMATION CONTACT: National Vaccine Program Office, U.S. 
Department of Health and Human Services, Room 715-H, Hubert H. Humphrey 
Building, 200 Independence Avenue SW., Washington, DC 20201. Phone: 
(202) 690-5566; Fax: (202) 690-4631; email: nvpo@hhs.gov.

SUPPLEMENTARY INFORMATION: Pursuant to Section 2101 of the Public 
Health Service Act (42 U.S.C. 300aa-1), the Secretary of Health and 
Human Services was mandated to establish the National Vaccine Program 
to achieve optimal prevention of human infectious diseases through 
immunization and to achieve optimal prevention against adverse 
reactions to vaccines. The National Vaccine Advisory Committee was 
established to provide advice and make recommendations to the Director 
of the National Vaccine Program on matters related to the Program's 
responsibilities. The Assistant Secretary for Health serves as Director 
of the National Vaccine Program.
    The topics to be discussed at the NVAC meeting will include 
seasonal influenza, implementation of the National Vaccine Plan, and 
vaccine research and development. The meeting agenda will be posted on 
the NVAC Web site: https://www.hhs.gov/nvpo/nvac prior to the meeting. 
Public attendance at the meeting is limited to space available. 
Individuals who plan to attend and need special assistance, such as 
sign language interpretation or other reasonable accommodations, should 
notify the National Vaccine Program Office at the address/phone listed 
above at least one week prior to the meeting. Members of the public 
will have the opportunity to provide comments at the NVAC meeting 
during the public comment periods on the agenda. Individuals who would 
like to submit written statements should email or fax their comments to 
the National Vaccine Program Office at least five business days prior 
to the meeting.

    Dated: May 1, 2012.
Bruce Gellin,
Director, National Vaccine Program Office, Executive Secretary, 
National Vaccine Advisory Committee.
[FR Doc. 2012-10986 Filed 5-7-12; 8:45 am]
BILLING CODE 4150-44-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.